Literature DB >> 21267131

Management of outpatient burns.

G D Waslen.   

Abstract

The severity of burns depends on the depth and extent of body surface involved. The total body surface area (TBSA) involved can be estimated by the 'rule of nines'; body locations are 9% of body surface or multiples of nine. Depth and TBSA can be used to classify burns as minor, moderate, or critical. Diagnosis depends on history and physical examination. Most burns can be treated in an outpatient setting. Treatment should include debriding necrotic tissue, preventing infection and encouraging healing. Specific treatment of burns of the face, hands, trunk and feet is described. Follow-up should include assessing healed wounds for the development of hypertrophic scars, and preventing such scars if possible.

Entities:  

Year:  1986        PMID: 21267131      PMCID: PMC2327630     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  6 in total

1.  Techniques for decreasing scar formation and contractures in the burned patient.

Authors:  D L Larson; S Abston; E B Evans; M Dobrkovsky; H A Linares
Journal:  J Trauma       Date:  1971-10

2.  Vascular injuries of the thoracic outlet.

Authors:  D L Bricker; G P Noon; A C Beall; M E DeBakey
Journal:  J Trauma       Date:  1970-01

Review 3.  Characteristics and uses of biologic dressings and skin substitutes.

Authors:  B A Pruitt; N S Levine
Journal:  Arch Surg       Date:  1984-03

4.  Outpatient treatment of burns.

Authors:  J A Moylan
Journal:  Postgrad Med       Date:  1983-03       Impact factor: 3.840

5.  Topical therapy.

Authors:  W W Monafo; V H Ayvazian
Journal:  Surg Clin North Am       Date:  1978-12       Impact factor: 2.741

6.  Use of systemic antibiotics in the burned patient.

Authors:  D R Haburchak; B A Pruitt
Journal:  Surg Clin North Am       Date:  1978-12       Impact factor: 2.741

  6 in total
  1 in total

1.  Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.

Authors:  Ruth Bolier; Elsemieke S de Vries; Albert Parés; Jeltje Helder; E Marleen Kemper; Koos Zwinderman; Ronald P Oude Elferink; Ulrich Beuers
Journal:  Trials       Date:  2017-05-23       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.